Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-7702/7703-03 combination therapy in unresectable BRAF V600-mutant thyroid cancer
jRCT2011200018Phase 2Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of encorafenib and binimetinib in thyroid cancer, sponsored by Ono Pharmaceutical. Primary endpoint: Objective response rate (central review). Started Mar 2021; status: completed.
02
Drugs
encorafenibbinimetinib
03
Conditions
thyroid cancer
Beyond the preview
Go deeper on jRCT2011200018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011200018.